Oncology

Featured

Robert Rifkin, MD, Rocky Mountain Cancer Centers

Conference Coverage

Prophylactic Tocilizumab Prior to Outpatient Step-Up Administration of Teclistamab Lowers CRS Among Patients With R/R MM

06/04/2024

Featuring Robert Rifkin, MD

Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.

Robert Rifkin, MD, discusses...

06/04/2024

Oncology

David Andorsky, MD, Rocky Mountain Cancer Centers

Videos

Significance of Patient Enrollment in Lymphoma Clinical Trials, Particularly Among Older Patients

06/04/2024

Featuring David Andorsky, MD

David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.

David Andorsky, MD, shares...

06/04/2024

Oncology

Videos

Novel Updates in DLBCL and MCL Treatment Research From the 2024 ASCO Meeting

06/04/2024

Featuring John Burke, MD

John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.

John Burke, MD, discusses some...

06/04/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/03/2024

Xichun Hu, MD, PhD

Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast...

Xichun Hu, MD, PhD, Fudan...

06/03/2024

Oncology

Conference Coverage

Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma

06/03/2024

Don Dizon, MD

Don Dizon, MD, discusses the results from the phase 2 BrUOG 354 trial evaluating nivolumab with/without ipilimumab among patients with ovarian and extra-renal clear cell carcinoma.

Don Dizon, MD, discusses the...

06/03/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer

06/03/2024

Jane Meisel, MD

Jane Meisel, MD, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.

Jane Meisel, MD, discussed...

06/03/2024

Oncology

Conference Coverage

Subcutaneous Epcoritamab Demonstrated Efficacy Among Patients With R/R DLBCL and FL Treated in the Outpatient Setting

06/03/2024

Featuring David Andorsky, MD

David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.

David Andorsky, MD, discussed...

06/03/2024

Oncology

Conference Coverage

Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer

06/02/2024

Suresh Ramalingam, MD

Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.

Suresh Ramalingam, MD, discussed...

06/02/2024

Oncology

Areej El-Jawahri, MD, Massachusetts General Hospital

Conference Coverage

Palliative Care Significantly Improves Discussion and Documentation of End-of-Life Care Preferences Among Patients With AML and MDS

06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...

Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...

Areej El-Jawahri MD, discusses...

06/01/2024

Oncology

Conference Coverage

ARV-766 for Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Androgen Receptor LBD Mutations

06/01/2024

Daniel Petrylak, MD

Daniel Petrylak, MD, discussed results from a phase 1/2 study that demonstrated that ARV-766 was well tolerated and showed promising clinical activity among patients with androgen receptor LBD-mutated metastatic castration-resistant prostate...

Daniel Petrylak, MD, discussed...

06/01/2024

Oncology

Conference Coverage

Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

06/01/2024

Natasha Leighl, MD

Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.

Natasha Leighl, MD, discussed...

06/01/2024

Oncology

Insights From the ESMO Congress

Conference Coverage

Relatlimab Added to Nivolumab Has Robust Anti-Tumor Activity in Advanced Melanoma

11/22/2023

Stephanie Holland

Biomarker analyses from patients enrolled in the RELATIVITY-047 trial revealed relatlimab added to nivolumab has robust anti-tumor activity among patients with advanced melanoma with lower CD8+ T cell infiltration.

Biomarker analyses from patients...

11/22/2023

Oncology

Quiz

Tisotumab Vedotin for Cervical Cancer

11/21/2023

Oncology

Conference Coverage

Avelumab Plus Cetuximab for Advanced Cutaneous Squamous Cell Carcinoma

11/20/2023

Featuring Juergen C. Becker, MD, PhD

Featuring Juergen C. Becker, MD, PhD ...

Juergen C. Becker, MD, PhD, German Cancer Consortium, discusses preliminary findings from the phase 2 AliCe study combining avelumab with cetuximab for patients with advanced, unresectable cutaneous squamous cell carcinoma.

Juergen C. Becker, MD, PhD,...

11/20/2023

Oncology

Arlene Siefker-Radtke, MD, MD Anderson Cancer Center

Videos

Erdafitinib Shows Similar OS to Pembrolizumab Among Patients With FGFR-Altered Advanced/Metastatic Urothelial Carcinoma

11/16/2023

Featuring Arlene Seifker-Radtke, MD

Featuring Arlene Seifker-Radtke, MD ...

Arlene Siefker-Radtke, MD, discusses the THOR trial which found that erdafitinib had a similar OS to pembrolizumab among patients with advanced or metastatic urothelial carcinoma.

Arlene Siefker-Radtke, MD,...

11/16/2023

Oncology

Videos

Using Liquid Biopsy to Guide Post-Surgical Treatment Among Patients With Colon Cancer

11/16/2023

Featuring Sara Lonardi, MD

Sara Lonardi, MD, shares results from the PEGASUS trial which found post-surgical liquid biopsy may be used to guide the clinical management of patients with high-risk stage II or stage III colon cancer.

Sara Lonardi, MD, shares results...

11/16/2023

Oncology

Kohei Shitara, MD, PhD, National Cancer Center Hospital East

Videos

Perioperative Pembrolizumab Plus Chemotherapy for Resectable Gastric or Gastroesophageal Junction Cancer

11/14/2023

Featuring Kohei Shitara, MD, PhD

Featuring Kohei Shitara, MD, PhD ...

In the KEYNOTE-585 study, perioperative pembrolizumab plus chemotherapy improved the pathological complete response among patients with locally advanced, resectable gastric or gastroesophageal (G/GEJ) cancer, but not the event-free survival.

In the KEYNOTE-585 study,...

11/14/2023

Oncology

Quiz

Adjuvant Radiotherapy Following Radical Prostatectomy

11/13/2023

Allison Casey

Test your knowledge on the results from RADICALS RT trial evaluating adjuvant radiotherapy after radical prostatectomy.

Test your knowledge on the...

11/13/2023

Oncology

Conference Coverage

Static and Dynamic Biomarkers to Optimize Adjuvant Therapy in Luminal Early Breast Cancer

11/10/2023

Featuring Oleg Gluz, MD

Oleg Gluz, MD, Evangelical Bethesda Hospital, Breast Center Niederrhein, Mönchengladbach, Germany, discusses results from the prospective WSG-ADAPT HR+/HER- trial.

Oleg Gluz, MD, Evangelical...

11/10/2023

Oncology

News

Adjuvant Radiotherapy Provided No Benefit Among Patients With Prostate Cancer Post-Radical Prostatectomy

11/10/2023

Allison Casey

Results from the phase 3 RADICALS-RT trial found there was no meaningful benefit derived from adjuvant radiotherapy following radical prostatectomy for patients with prostate cancer.

Results from the phase 3...

11/10/2023

Oncology

News

Niraparib Plus Abiraterone Acetate and Prednisone for BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Allison Casey

Niraparib plus abiraterone acetate and prednisone improved several outcomes measures, including overall survival, among patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Niraparib plus abiraterone...

11/10/2023

Oncology

Insights From the ASCO Annual Meeting

Conference Coverage

Trastuzumab Deruxtecan Improves Progression-Free Survival Among Patients With HER2-Low Metastatic Breast Cancer

06/06/2024

Allison Casey

According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.

According to first results from...

06/06/2024

Oncology

Conference Coverage

Pembrolizumab Plus Sacituzumab Govetican for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer

06/06/2024

Allison Casey

According to results from a phase 2 trial, pembrolizumab added to sacituzumab govetican showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.

According to results from a...

06/06/2024

Oncology

Conference Coverage

Prophylactic Tocilizumab Prior to Outpatient Step-Up Administration of Teclistamab Lowers CRS Among Patients With R/R MM

06/04/2024

Featuring Robert Rifkin, MD

Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.

Robert Rifkin, MD, discusses...

06/04/2024

Oncology

Conference Coverage

Ceralasertib Plus Olaparib Demonstrated Promising Clinical Activity Among Patients With Recurrent Platinum-Sensitive Ovarian Cancer

06/04/2024

Stephanie Holland

Results from a phase 2 study found that ceralasertib plus olaparib was well tolerated and demonstrated promising clinical activity among patients with recurrent platinum-sensitive ovarian cancer, regardless of tumor genomic instability.

Results from a phase 2 study...

06/04/2024

Oncology

Videos

Novel Updates in DLBCL and MCL Treatment Research From the 2024 ASCO Meeting

06/04/2024

Featuring John Burke, MD

John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.

John Burke, MD, discusses some...

06/04/2024

Oncology

Conference Coverage

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

06/03/2024

Xichun Hu, MD, PhD

Xichun Hu, MD, PhD, Fudan...

06/03/2024

Oncology

Conference Coverage

Immunotherapy Shows Activity Among Patients With Gynecologic Clear Cell Carcinoma

06/03/2024

Don Dizon, MD

Don Dizon, MD, discusses the results from the phase 2 BrUOG 354 trial evaluating nivolumab with/without ipilimumab among patients with ovarian and extra-renal clear cell carcinoma.

Don Dizon, MD, discusses the...

06/03/2024

Oncology

Conference Coverage

Datopotamab Deruxtecan for Patients With Previous Treated HR-Positive, HER2-Negative Breast Cancer

06/03/2024

Jane Meisel, MD

Jane Meisel, MD, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.

Jane Meisel, MD, discussed...

06/03/2024

Oncology

Conference Coverage

Neoadjuvant Sintilimab Plus Chemotherapy Shows Promising Activity Among Patients With Locally Advanced Cervical Cancer

06/03/2024

Allison Casey

According to phase 2 data, sintilimab plus paclitaxel and cisplatin in the neoadjuvant setting showed encouraging antitumor activity among patients with locally advanced cervical cancer.

According to phase 2 data,...

06/03/2024

Oncology

Conference Coverage

Olaparib Alone As a Chemotherapy-Free Approach Post-Cytoreduction for Patients With Platinum-Sensitive High-Grade Serous Ovarian Cancer

06/03/2024

Allison Casey

According to phase 2 data to be reported at the 2024 ASCO Annual Meeting, olaparib following secondary cytoreduction may be as effective as chemotherapy plus olaparib while being less toxic among patients with resectable, platinum-sensitive,...

According to phase 2 data to be...

06/03/2024

Oncology

Biological Pathway Reviews

Live Meetings

Recent News

Conference Coverage

Ceralasertib Plus Olaparib Demonstrated Promising Clinical Activity Among Patients With Recurrent Platinum-Sensitive Ovarian Cancer

06/04/2024

Stephanie Holland

Results from a phase 2 study...

06/04/2024

Oncology

News

FDA Approves Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma

06/03/2024

Amber Denham

The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.

The U.S. Food and Drug...

06/03/2024

Oncology

Conference Coverage

Lorlatinib Provides Longest Progression Free Survival Ever Seen for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/02/2024

Allison Casey

According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.

According to updated data...

06/02/2024

Oncology

Conference Coverage

Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer

06/02/2024

Allison Casey

The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.

The phase 2 KEYVIBE-005 study...

06/02/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

According to updated results...

05/31/2024

Oncology

News

Oral Decitabine and Cedazuridine Plus Venetoclax Shows Efficacy, Safety for Older or Unfit Patients With AML

05/31/2024

By Gina Tomaine

Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.

Decitabine and cedazuridine plus...

05/31/2024

Oncology

News

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Patients With Advanced Extranodal Natural Killer/T-Cell Lymphoma

05/29/2024

Amber Denham

According to results from a phase 2 trial, the combination of sintilimab with pegaspargase, gemcitabine, and oxaliplatin exhibits efficacy and safety as a frontline regimen among patients with advanced extranodal natural killer/T-cell...

According to results from a...

05/29/2024

Oncology

News

Abemaciclib Plus Nonsteroidal Aromatase Inhibitor Improved Survival Outcomes Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

05/23/2024

Stephanie Holland

According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...

According to final overall...

05/23/2024

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology

News

Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ

05/22/2024

Stephanie Holland

According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...

According to results from cohort...

05/22/2024

Oncology